The Compass to CARE Forum - MS Virtual event video

The Compass to CARE Forum - MS Virtual event video



CLICK ABOVE to play the Video







Stay Healthy, Stay Home and Wash Your Hands

Click HERE to Subscribe for the MS Beacon Newsletter
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Remember to subscribe to our:  MS Learning Channel on @YouTube



Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  24 Hits

Copyright

© M.S. Views & News

24 Hits

The Importance of Interdisciplinary Care in MS

Stay Healthy, Stay Home and Wash Your Hands

Click HERE to Subscribe for the MS Beacon Newsletter
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic detailed the need to incorporate interdisciplinary care and behavioral medicine in commonplace MS practice.


Amy Sullivan, PsyD, ABBP
Meeting the all the needs of patients, including those related to mental health, is among the top priorities for clinicians when treating individuals with Multiple Sclerosis (MS). The heightened ability to change and adapt treatment strategies with input from multiple experts is what separates interdisciplinary care from other methods of care. 

As the director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic, Amy Sullivan, PsyD, ABBP, has a strong passion for utilizing interdisciplinary care and behavioral medicine into standard MS care practices. Sullivan is expected to present “Science, Art, and Practice of Behavioral Medicine,” at the 2020 Consortium of Multiple Sclerosis (CMSC) Virtual Annual Meeting, May 26–29.

Amy Sullivan, MD: Interdisciplinary care is the wave of the future for patients with MS. At the Mellen Center, we’ve been really lucky to have this for several decades. It is so important because we all look at the patient from a different angle. When we’re able to do that, and come together, we give the patient a better opportunity to have a better outcome. We’re treating them from the mind, the body—really everything that the patient needs. 

What is the greatest need that can be met by incorporating behavioral medicine into care? What work still needs to be done?

There is a lot of work that needs to be done in terms of creating a behavioral medicine practice in all of these major multidisciplinary centers. I don’t think that MS care is complete without behavioral medicine. The statistics in my presentation show that depression and anxiety occur 3 to 4 times as often in a patient with MS than the general population. If we’re not treating their behavioral medicine needs, we’re not treating them correctly as a whole. It is imperative that we start putting more emphasis on behavioral medicine and the MS care.

CONTINUE READING



::::::::::::::::::::::::::::::::::::::;;;;;;;;;;;;;;;;;;;;;::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Information Shared by: MSViewsandNews
to and for those affected by Multiple Sclerosis
::::::::::::::::::::::::::::::::::::::;;;;;;;;;;;;;;;;;;;;;:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::


Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
(Originally posted by Stuart)
  4 Hits

Copyright

© M.S. Views & News

4 Hits

What's New in Stem Cells? Expert Discusses Hematopoietic Status and Newer Mesenchymal Approaches

Stay Healthy, Stay Home and Wash Your Hands

Click HERE to Subscribe for the MS Beacon Newsletter
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Stem cells are attractive for MS treatment because they are capable of undergoing self-renewal and differentiating into multiple different cell families, potentially allowing for correction of aberrant processes in the immune system, said Mark Freedman, MSC, MD, a recognized expert in stem cell therapeutics.Stem cell treatments (SCT) have been described as a promising and powerful therapeutic strategy for severe Multiple Sclerosis (MS), a highly experimental approach, or a dubious sham treatment preying on unwary patients. So, which is correct? This depends upon which type of SCT one is discussing. Mark S. Freedman, MSC, MD, Professor of Neurology at the University of Ottawa in Ontario, Canada, provided listeners with a status update on SCT at the Consortium of Multiple Sclerosis Centers (CMSC) Virtual Annual Meeting on Thursday, May 28.




The first description, promising and powerful, applies to autologous hematopoietic SCT (aHSCT), the most advanced procedures to date in terms of research for MS. The rationale for this approach, also called bone marrow transplant, is: complete removal of the diseased immune system to halt ongoing MS immune-mediated damage to the central nervous system; purified bone marrow stem cells may be capable of fully restoring a functional immune system; the reconstituted immune system will not likely result in re-development of the previous aberrant immune response; and transplanted stem cells may also be capable of inducing repair.

aHSCT must be done in combination with chemotherapy in order to fully ablate the existing immune system. In fact, this is the efficacious part of the treatment, while the infused stem cells are what keeps the patient alive to allow the immune system to reboot. The efficacy and safety equation for different aHSCT techniques depends in part upon what type of chemoablative conditioning regimen is used prior to infusing the stem cells. A more extreme myeloablative regimen is the most effective but also the most risky. This approach involves complete ablation of all elements of the hematopoietic system using total body radiation and chemotherapy. The lymphoablative approach, meanwhile, is a less-toxic, neutrophil-sparing regimen involving removal of cells outside of the bone marrow. This involves chemotherapy prior to infusion of the stem cells, but sacrifices some efficacy.
Another variable is whether the procedure involves purifying for CD34+ cells. In this technique, done only in specialized facilities, CD34-reactive cells are separated from non-reactive cells via a magnetic process. This selects out stem cells that are better for grafting and believed to have a better chance of eliminating immune cells that may lead to disease recurrence.





::::::::::::::::::::::::::::::::::::::;;;;;;;;;;;;;;;;;;;;;::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Information Shared by: MSViewsandNews
to and for those affected by Multiple Sclerosis
::::::::::::::::::::::::::::::::::::::;;;;;;;;;;;;;;;;;;;;;:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::


Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
(Originally posted by Stuart)
  24 Hits

Copyright

© M.S. Views & News

24 Hits

Bristol Myers Squibb Announces Commercial Launch and Availability of ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis

Stay Healthy, Stay Home and Wash Your Hands

Click HERE to Subscribe for the MS Beacon Newsletter
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~



Press Release



ZEPOSIA is the first and only approved sphingosine-1-phosphate (S1P) receptor modulator with no genetic test or first dose observation at initiation* 1,2,3

ZEPOSIA 360 Support™ Program offers support to help appropriate MS patients access ZEPOSIA

MONDAY, JUNE 1, 2020 6:59 AM EDT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that ZEPOSIA® (ozanimod) 0.92 mg, a new once-daily oral medication for adults for the treatment of relapsing forms of Multiple Sclerosis (RMS), including Clinically Isolated Syndrome, relapsing-remitting disease, and active Secondary Progressive disease, is now commercially available in the U.S. ZEPOSIA was approved by the U.S. Food and Drug Administration (FDA) on March 25, 2020.1

*ZEPOSIA is the only approved sphingosine-1-phosphate (S1P) receptor modulator that offers appropriate RMS patients an initiation with no genetic test and no first dose observation.1,2,3 An up-titration scheme should be used to reach the maintenance dosage of ZEPOSIA, as a transient decrease in heart rate and atrioventricular conduction delays may occur.1 Before initiation of treatment with ZEPOSIA, all patients require assessments including a recent complete blood count including a lymphocyte count (within six months or after discontinuation of prior MS therapy), an ECG to determine whether preexisting conduction abnormalities are present, a recent liver function test (within six months), and consideration of current and prior medications, including vaccinations.1 For patients with a history of uveitis or macular edema, an ophthalmic assessment is required.1

“We are pleased to now bring ZEPOSIA, an important new once daily treatment option, to RMS patients,” said Tina Deignan, vice president and U.S. head of immunology, Bristol Myers Squibb. “ZEPOSIA is the first and only S1P that requires no first dose observation,1,2,3 which may minimize the number of interactions RMS patients need to have with healthcare practioners prior to initiating therapy during this unprecedented time of social distancing.”

ZEPOSIA is contraindicated in patients who in the last six months experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III/IV heart failure; patients who have a presence of Mobitz type II second or third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial, unless the patient has a functioning pacemaker; patients with severe untreated sleep apnea; and patients taking a monoamine oxidase inhibitor.1 ZEPOSIA is associated with the following Warnings and Precautions: increased risk of infections, bradyarrhythmia and atrioventricular conduction delays, liver injury, fetal risk, increased blood pressure, respiratory effects, macular edema, posterior reversible encephalopathy syndrome, additive immunosuppressive effects from prior immune-modulating treatments, severe increase in disability after stopping ZEPOSIA, and immune system effects after stopping ZEPOSIA.1 Please see Important Safety Information for additional details.1 The most common adverse reactions (incidence ≥4%) were upper respiratory infection, hepatic transaminase elevation, orthostatic hypotension, urinary tract infection, back pain, and hypertension.1







Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
(Originally posted by Stuart)
  46 Hits

Copyright

© M.S. Views & News

46 Hits

Multiple sclerosis and your eyes -- Nystagmus; Twitching; Optic neuritis, and More

COVID-19 is unprecedented and rapidly changing situation.
Get the latest public health information from CDC: https://www.coronavirus.gov 
Stay Healthy, Stay Home and Wash Your Hands

Click HERE to Subscribe for the MS Beacon Newsletter



MS is characterized by the immune system damaging myelin — a substance that surrounds and protects nerve fibers. Damaged areas of myelin are referred to as plaques or lesions.
Demyelinating lesions can affect different parts of the CNS, including the optic nerves. One of the common early signs of MS is vision problems.

People with MS sometimes experience myoclonus. Myoclonus is sudden, involuntary twitching or quivering of a muscle or group of muscles.
It’s a reactive nerve cell misfire that sends the wrong signal to your muscles. This could be the result of demyelinating lesions from MS.

There are a variety of causes for an eye twitch in people with MS, such as nystagmus and internuclear ophthalmoplegia. Other eye conditions such as optic neuritis and diplopia are also known to affect many people with MS.

Nystagmus is uncontrolled repetitive vertical, horizontal, or circular eye movements. This makes it nearly impossible to steadily view objects.
Acquired nystagmus is not an uncommon symptom of MS, and often results in diminished vision and depth perception. It also can impact coordination and balance.
If you have visually disabling nystagmus, your doctor might recommend medications such as:
gabapentin (Neurontin)baclofen (Lioresal)memantine (Namenda)clonazepam (Klonopin)
Internuclear ophthalmoplegia (INO) is damage to the nerve fibers that coordinate both eyes in looking from side to side (horizontal movements). Vertical eye movements are not affected.
If INO is caused by a stroke (typically in older people), it usually only affects one eye. If it’s caused by MS (typically in younger people), it often affects both eyes.

Some studiesTrusted Source have indicated that INO is seen in about 23 percentTrusted Source of people with MS and that most people will experience a complete recovery.
For acute internuclear ophthalmoplegia, your doctor might recommend intravenous steroid therapy.


A common vision problem related to MS, optic neuritis is an inflammation of the optic nerve that can result in blurred vision, pain, and a sudden loss of vision — typically in one eye.

Rarely causing blindness, optic neuritis might result in the blurring of vision or a dark spot in the center of the visual field, known as a central scotoma.

Optic neuritis commonly improves on its own, but based on your specific situation, your doctor might recommend a steroid such as methylprednisolone administered intravenously, possibly followed with oral steroids.



....................................................................................

This article is posted and shared by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::


Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  17 Hits

Copyright

© M.S. Views & News

17 Hits

3 Techniques to Help You Overcome Anxiety and Stress

3 Techniques to Help You Overcome Anxiety and Stress
05.05.20 - BY JESSIE ACE - MultipleSclerosisNewsToday
Anxiety and stress are unhelpful for anyone’s mind or body, particularly with a chronic illness like multiple sclerosis
Feeling anxious or stressed is our brain’s mechanism to prepare the body for a potentially harmful threat. The brain releases a surge of chemicals to prepare the body for going into what’s called a fight-or-flight response. This response is meant to save our life when we are in danger.  

Click HERE to Subscribe for the MS Beacon Newsletter


However, most of the time, we’re not actually in physical danger. Rather, the danger is perceived. So how do we override this response by the brain and reduce anxiety? We must change our way of thinking and our physiology. 
What effect does anxiety have on our bodies? The released chemicals change our physiology. Blood vessels tighten, our heart pumps faster, and breathing is shallower, to name a few. 

How does anxiety affect someone with MS? Stress makes our bodies work harder, increasing fatigue and exacerbating other symptoms
Here’s how we hack our brain to avoid this:
Question whether the thing you’re anxious about is in your control. Most often, we don’t have control over the things that are worrying us.
I know that when I was a newly diagnosed 22-year-old with MS, I used to worry like crazy about the future and what my life would be like with this illness. 
Did worrying about my future at the time help? Nope! Did it make my anxious state almost unbearable? Yep. 
The only thing you can control are the actions you take today to create a better tomorrow.
That is why it is so important to do things like getting in the routine of a healthy diet for MS and exercising today so you can be healthier tomorrow. 
Here is a video I made to help explain what I mean: https://mmini.me/areweincontrol 
Use a breathing technique to override the brain’s fight-or-flight response. Breathing is super important for relaxing the body and cutting down those chemicals released by the brain. Breathing deeply sends more oxygen to the brain via the bloodstream. It pretty much tells your mind to calm down and chill out. 
Also, if you find yourself too anxious to sleep or you are struggling with insomnia, this is a great technique to try. 
Here is a video I made to explain more: https://mmini.me/Breathing
Reduce anxiety by naming five things around you. This is simple but effective. Why the heck does it work? Because it focuses your brain on what’s happening in the present. Naming the things around you also changes what’s going on in your brain. The left side of your brain, which is responsible for logic and reasoning, gets drowned out by the right side, which is the imaginative, creative, and emotional side. 
In essence, naming the things around you drives focus to the left side of your brain and cancels out the imaginative/emotional response that can run away with us and create scenarios in our minds of things that might happen.
Continue reading


....................................................................................

This article is posted and shared by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
(Originally posted by Stuart)
  30 Hits

Copyright

© M.S. Views & News

30 Hits

FDA Approves Bafiertam, (a Tecfidera) Generic, for Relapsing MS

FDA Approves Bafiertam, (a Tecfidera) Generic, for Relapsing MS



Banner Life Sciences Announces Final FDA Approval of BAFIERTAM for Multiple Sclerosis

BAFIERTAM™ (monomethyl fumarate), the bioequivalent alternative to Biogen’s Tecfidera® (Dimethyl Fumarate), is a new oral treatment option for relapsing forms of Multiple Sclerosis
Open path to commercialization

Click HERE to Subscribe for the MS Beacon Newsletter



April 30, 2020 07:05 AM Eastern Daylight Time

HIGH POINT, N.C.--(BUSINESS WIRE)--Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) granted final approval of BAFIERTAM™ (monomethyl fumarate) delayed-release capsules for the treatment of relapsing forms of Multiple Sclerosis (MS).

“The FDA’s final approval marks an important milestone for Banner and for patients living with relapsing-remitting Multiple Sclerosis,” said Franck Rousseau, M.D., Chief Executive Officer of Banner. “We are working diligently and are eager to bring this alternative treatment to physicians and patients as soon as possible.”

“As a practicing neurologist treating patients with MS, I’m encouraged that a lower dose of BAFIERTAM is equivalent to Tecfidera and may possibly lead to improved gastrointestinal tolerability for patients, especially early in the treatment regimen,” said Daniel Wynn, M.D. FACNS FAASM, Director, Clinical Research, Director Consultants in Neurology Multiple Sclerosis Comprehensive Care Center, Chicago, Illinois.

The FDA granted tentative approval of BAFIERTAM on November 16, 2018 under a New Drug Application (NDA) submitted under the 505(b)(2) filing pathway. BAFIERTAM, a novel fumarate bioequivalent alternative to a prodrug of BAFIERTAM, Tecfidera®1 (Dimethyl Fumarate) of Biogen Inc, met the required bioequivalence, safety, efficacy and quality standards for tentative approval. Final approval was pending the expiration of U.S. Patent Number 7,619,001 (“the ‘001 patent”) on June 20, 2020 protecting Biogen’s Tecfidera, or the outcome of pending litigation between Banner and Biogen regarding the patent.

In January 2019, Banner announced that the U.S. District Court for the District of Delaware had ruled in favor of Banner’s motion for judgment on the pleadings against Biogen, Inc. deciding BAFIERTAM does not infringe the ‘001 patent, thus permitting Banner to seek final FDA approval. On April 21, 2020, Banner announced that the United States Court of Appeals for the Federal Circuit had upheld the earlier Court’s decision.

About BAFIERTAM™ (monomethyl fumarate)

BAFIERTAM is a prescription medicine used to treat relapsing forms of Multiple Sclerosis (MS), to include Clinically Isolated Syndrome, relapsing-remitting disease, and active Secondary Progressive disease, in adults.

About Relapsing-Remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis (RRMS), the most common form of MS, is a debilitating autoimmune disease characterized by inflammatory attacks to the central nervous system followed by periods of remission. RRMS affects approximately 85 percent of patients diagnosed with MS, or an estimated 2 million people worldwide.2 There is no cure for MS and disease progression and degree of impairment vary widely by patient depending on the location and extent of nerve damage. Treatment regimens for RRMS focus on symptom management, slowing disease progression and reducing relapses.

SELECTED SAFETY INFORMATION

CONTRAINDICATIONS

BAFIERTAM is contraindicated in patients with known hypersensitivity to monomethyl fumarate, Dimethyl Fumarate, diroximel fumarate, or to any of the excipients of BAFIERTAM.

WARNINGS AND PRECAUTIONS

Anaphylaxis and Angioedema - BAFIERTAM can cause anaphylaxis and angioedema after the first dose or at any time during treatment. Signs and symptoms in patients taking Dimethyl Fumarate (the prodrug of BAFIERTAM) have included difficulty breathing, urticaria, and swelling of the throat and tongue. Patients should be instructed to discontinue BAFIERTAM and seek immediate medical care should they experience signs and symptoms of anaphylaxis or angioedema.

Progressive Multifocal Leukoencephalopathy - Progressive multifocal leukoencephalopathy (PML) has occurred in patients with MS treated with Dimethyl Fumarate (the prodrug of BAFIERTAM).
....................................................................................

This article is posted and shared by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
(Originally posted by Stuart)
  72 Hits

Copyright

© M.S. Views & News

72 Hits

New Study Links Obesity to Faster Nerve Loss in People with MS

Click HERE to Subscribe for the MS Beacon Newsletter


April 23, 2020
Johns Hopkins University researchers funded in part by the National MS Society report that people with MS who were obese experienced accelerated loss of optic nerve tissue compared to people of normal weight. The study followed 513 people with MS  for about four years. The authors suggest that, if confirmed, the findings show a link between a wellness factor – body weight -- and MS progression, and support studies that would track whether reducing weight can improve outcomes in MS.Optical coherence tomography (OCT) has been increasingly used as a research tool to detect and track damage that occurs to the nerves in the back of the eye. OCT scanning is done with a small machine that can fit into an examining room, is relatively inexpensive, painless and well tolerated.This team has previously shown that the rate of tissue thinning seen on OCT in people with MS over time reliably mirrors overall brain health and nerve loss, suggesting that OCT can show underlying disease progression.In this study, loss of tissue in a specific nerve layer in the back of the eye, called the ganglion cell and inner plexiform layer, was accelerated in people who were obese at the start of the study (defined as having a body mass index of 30 or higher).This study adds important evidence to previous findings that obesity worsens outcomes for people with MS. Understanding further the relation between obesity and nervous system health may also have implications for people with other health concerns.Obesity is considered a modifiable risk factor – learn more about healthy eating and taking control of your weight. Get information on food planning during the coronavirus pandemic from the U.S. Department of Agriculture.“Association of body mass index with longitudinal rates of retinal atrophy in multiple sclerosis” by Drs. Angeliki G Filippatou, Shiv Saidha and colleagues (The Johns Hopkins University School of Medicine, Baltimore, MD) was published on April 16, 2020 in the Multiple Sclerosis Journal.

Source link








This article is posted and shared by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
(Originally posted by Stuart)
  45 Hits

Copyright

© M.S. Views & News

45 Hits

MS Society-Supported Wellness Research Group Publishes Strategies for Improving Diet Studies in People with MS

April 27, 2020
Can a person’s diet make their MS worse or better? Is there an ideal diet for people with MS? Evidence-based answers to these and other questions require results from well-designed studies. A Wellness Research Group supported by the National MS Society has published new strategies for improving diet studies in people affected by MS, based on studies that have already been completed or are underway. These recommendations can inform studies going forward to ensure they provide the answers people and their healthcare providers need to enhance well being. See how a healthy diet, regular exercise, stress management and other wellness strategies can help you manage your symptoms and feel your best.

Click HERE to Subscribe for the MS Beacon Newsletter

As part of its ongoing wellness initiative, the National MS Society convened a group of researchers with experience in MS and  diet-related research, as well as a person living with MS, to develop recommendations regarding unmet needs and opportunities in diet -related research. The group’s primary mission is to promote scientific evidence to support lifestyle, behavioral, and psychosocial approaches for promoting wellness in people living with MS.Based on lessons learned from recent or ongoing diet studies, the group discussed several recommendations going forward, including the following:Begin dietary studies with an education session led by a nutritionist and include local options for food shopping. Include partners/significant others, to ease implementation at home. Make sure that people fully understand the dietary interventions they are being asked to follow, and what will be expected in terms of time, finances, and travel.Let people who already cook be creative with the diet plan to increase flexibility, but include highly specific guidance for people who do not, to decrease anxiety.Depression, anxiety, fatigue, and mobility impairments – common in the course of MS – may affect adherence and need to be considered in study design.Studies may involve collecting blood, urine or stool samples, but it’s important to balance the need for samples with the fact that collecting them too frequently may deter recruitment or compliance. “Conducting dietary intervention trials in people with multiple sclerosis: Lessons learned and a path forward” is published by Dr. Kathryn Fitzgerald, Dr. Ellen Mowry (Johns Hopkins University, Baltimore) and colleagues in the journal MS & Related Disorders.

About Multiple Sclerosis

Continue



:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

This article is posted and shared by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  56 Hits

Copyright

© M.S. Views & News

56 Hits

What We Know About Multiple Sclerosis and COVID-19 - a Video by Stephen Krieger, MD

What We Know About Multiple Sclerosis and COVID-19 - a Video by Stephen Krieger, MD
Stephen Krieger, MD
DISCLOSURES 
April 17, 2020





Click HERE to Subscribe for the MS Beacon Newsletter

....................................................................................

This article is posted and shared by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
(Originally posted by Stuart)
  54 Hits

Copyright

© M.S. Views & News

54 Hits

Starting Mayzent Early of Greater Benefit in SPMS, 5-Year Trial Data Show

Starting Mayzent Early of Greater Benefit in SPMS, 5-Year Trial Data Show
APRIL 22, 2020 -  BY MARISA WEXLER, MS


Click HERE to Subscribe for the MS Beacon Newsletter


People with secondary progressive multiple sclerosis (SPMS) who began treatment with Mayzent early and continued its use for years are less likely to experience disability progression than those starting the medication later in their disease course, five-year data from the EXPAND study suggest.
Data from this same Phase 3 clinical trial further suggest that Mayzent can help preserve important tissues in the brain, delaying physical disability and slowing cognitive decline.
The findings were published in a supplementary issue of the journal Neurology following the cancellation of the 2020 American Academy of Neurology Annual Meeting due to the COVID-19 pandemic.
Mayzent (siponimod), developed by Novartis, is approved to treat active SPMS in both the United States and Europe. The oral therapy belongs to a class of medications called S1P receptor modulators. These work by ‘trapping’ immune cells in lymph nodes (immunological structures), which can limit the inflammation that causes nervous system damage in MS.
The Phase 3 EXPAND clinical trial (NCT01665144) is evaluating the safety and efficacy of Mayzent in people with SPMS. In the first part of this Novartis-sponsored study, participants were given either Mayzent or a placebo tablet for about three years. Results from this core part of the study, released in 2017, showed that Mayzent significantly slowed disability progression and cognitive decline compared to the placebo.
Click to continue reading from MS News Today


:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Please subscribe to the: 
   MS Learning Channel on @YouTube

Click Red Box on banner to opt-in
....................................................................................

This article is posted and shared by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
(Originally posted by Stuart)
  29 Hits

Copyright

© M.S. Views & News

29 Hits

OCREVUS® (ocrelizumab) Pregnancy Registry

OCREVUS® (ocrelizumab) Pregnancy Registry
OCREVUS® (Ocrelizumab) Pregnancy Registry


Do you have Multiple Sclerosis (MS) and are you pregnant? Then you may be able to take part in a global registry of women with MS who are pregnant and either have or have not received OCREVUS® (Ocrelizumab) during or within 6 months before their pregnancy.



About pregnancy and Multiple Sclerosis

The effects of a particular medicine on the health of an unborn baby are often unknown because pregnant women are not usually included in clinical research studies to test a potential new medicine. Pregnancy registries aim to collect information that could help women and their healthcare providers make more informed decisions about using a particular medicine during pregnancy in the future.


This article is posted and shared by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
(Originally posted by Stuart)
  78 Hits

Copyright

© M.S. Views & News

78 Hits

COVID-19 and MS - Global Data Sharing Initiative

https://msdataalliance.com/covid-19/covid-19-and-ms-global-data-sharing-initiative/#lnk01

#DataSavesLives – #MSCOVID19

As the COVID-19 pandemic unfolds across the globe, the demand for data on the impact of the novel coronavirus on people with Multiple Sclerosis (MS) grows rapidly.
This information is crucial for people with MS and clinicians to make evidence-based decisions on how to manage their condition during the pandemic or in case of a COVID-19 infection.
MS Data Alliance and the MS International Federation have teamed up to set up a Global Data Sharing Initiative and are calling for individuals and organisations across the global MS movement to get involved.  Watch our animation.

Click HERE to Subscribe for the MS Beacon Newsletter



Follow our progress and sign up to our mailing list to receive regular updates on the initiative.



============================================
This article is posted and shared by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
(Originally posted by Stuart)
  76 Hits

Copyright

© M.S. Views & News

76 Hits

New 6-Year Data for Genentech’s Ocrevus (ocrelizumab) Show Earlier Treatment Initiation Nearly Halves Risk of Needing Walking Aid in Relapsing Multiple Sclerosis

Post-hoc analysis from 6 years of Phase III open-label extension studies showed Ocrevus treatment reduced the risk of needing a walking aid (EDSS≥6) by 49% in relapsing Multiple Sclerosis (RMS) patients compared with patients who switched from Interferon Beta-1a two years later –
– Separate analysis showed Ocrevus slowed thalamic volume loss in patients with RMS and Primary Progressive MS (PPMS) vs. Interferon Beta-1a and placebo, respectively –
– More than 150,000 people have been treated with Ocrevus globally, in clinical trial and real-world settings; data continue to show a consistent and favorable benefit-risk profile –

Click HERE to Subscribe for the MS Beacon Newsletter
South San Francisco, CA -- April 27, 2020 --
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new analyses of Phase III OPERA I and OPERA II studies, as well as the open-label extensions, showing that Ocrevus® (Ocrelizumab) treatment reduced the risk of disease and disability progression in RMS and PPMS. These new analyses add additional evidence to the benefit-risk profile of Ocrevus, including the impact of MS on people’s daily lives. The data were selected for the 72nd American Academy of Neurology (AAN) Annual Meeting and will be made available online via virtual presentation in the coming weeks (in lieu of an in-person event).
“For people with MS, maintaining mobility for as long as possible is very important. We are encouraged by these new longer-term analyses showing that earlier initiation of Ocrevus treatment may reduce the risk of needing a walking aid by nearly 50 percent over six years,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “Slowing MS progression earlier in the disease course – not just treating relapses – may bring additional clinically meaningful outcomes to people living with this disease.”
Effect of Ocrevus on disability progression and risk of needing a walking aid in patients with RMS
Earlier treatment with Ocrevus may delay the risk of needing a walking aid compared to those who switched from Interferon Beta-1a two years later in a new post-hoc analysis from the open-label extension of the Phase III OPERA studies in RMS. The risk was measured by the length of time until a person reached a score on the Expanded disability Status Scale of 6 or greater (EDSS≥6) that was sustained for at least 48 weeks. People treated with Ocrevus had a 49% reduction in the risk of needing a walking aid compared to those that received Interferon Beta-1a over 6 years of study (4.3% vs. 7.2%*; p=0.0042). Safety profiles in the double-blind period and open-label extension were generally consistent.
Effect of Ocrevus on disease progression measured by thalamic atrophy
Ocrevus progressively slowed thalamic atrophy (as measured by change in thalamic volume) in patients with RMS or PPMS. Results from the double-blind periods of the Phase III OPERA I, OPERA II and ORATORIO studies showed significantly less thalamic atrophy compared with Interferon Beta-1a and placebo, respectively (both pContinue reading by clicking here


....................................................................................

This article is posted and shared by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  147 Hits

Copyright

© M.S. Views & News

147 Hits

Five Strategies for Safe Shopping

Even if you’re staying home whenever possible and practicing social distancing guidelines, going to the grocery store can be stressful and put you at greater risk of infection. Fortunately, there are a growing number of grocery delivery and curbside pick-up services — from national companies like Amazon and Instacart to local markets and restaurants that are adapting to the crisis. Jean Dobbs walks you through how to successfully navigate some of the options

continue reading



Click HERE to Register for the MS Beacon Newsletter


....................................................................................

This article is posted and shared by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
(Originally posted by Stuart)
  28 Hits

Copyright

© M.S. Views & News

28 Hits

Coronavirus and MS Reporting Database Announced by Consortium of Multiple Sclerosis Centers & National Multiple Sclerosis Society

....................................................................................

This article is posted and shared by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
(Originally posted by Stuart)
  81 Hits

Copyright

© M.S. Views & News

81 Hits

4-7-8 BREATH

4-7-8 BREATH
Provided by Megan Weigel, DNP - from First Coast Integrative Medicine



Of course you can print, hang in your home, and practice whenever you want



Click HERE to Register for the MS Beacon Newsletter

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
(Originally posted by Stuart)
  51 Hits

Copyright

© M.S. Views & News

51 Hits

Beyond Motor Symptom Wearing-off in Parkinson’s Disease – What Are We Missing?

Beyond Motor Symptom Wearing-off in Parkinson’s Disease – What Are We Missing?

European Neurological Review. 2020;15(Suppl. 1):2–7

Abstract

In the treatment of Parkinson’s disease (PD), wearing-off refers to the recurrence of motor (and non-motor) symptoms typically preceding scheduled doses of anti-parkinsonian medication. These can exert a substantial functional burden on the patient, are a frequent occurrence in patients with PD, can occur early in the disease, and most individual symptoms are progressive. As such, efforts should be made to detect wearing-off as early as possible so that appropriate therapeutic action can be taken to mitigate symptoms. Here we present the highlights of a satellite symposium held at the 2019 International Congress of Parkinson’s disease and Movement Disorders, Nice, France, discussing the clinical spectrum of wearing-off symptoms, including both motor and non-motor features, the challenges clinicians face in the management of wearing-off, our current understanding regarding the time course of motor fluctuations and how this has evolved beyond the classical view of PD staging, and available treatments to mitigate both motor and non-motor symptoms.

Keywords

#Parkinson’s disease, wearing-off, motor symptoms, non-motor symptoms

Disclosure

Olivier Rascol has served as a consultant or on advisory boards for AbbVie, Adamas, Acorda Therapeutics, Addex, AlzProtect, Apopharma, AstraZeneca, Bial, Biogen, Britannia, Bukwang Pharmaceutical Co., Ltd, Clevexel, Denali Therapeutics, INC Reasearch, Lundbeck, Lupin, Merck, MundiPharma, Neuratris, NeuroDerm, Novartis, ONO Pharma, Osmotica, Oxford Biomedica, Parexel, Pfizer, Prexton Therapeutics, Quintiles, Sanofi, Servier, Sunovion, Theranexus, Takeda, Teva, UCB, Vectura, Watermark Research, XenoPort, XO and Zambon; has received grants from the French National Research Agency (ANR), University Hospital Centre of Toulouse, France Parkinson, INSERM-DHOS Translational Clinical Research, Michael J Fox Foundation, Hospital Clinical Research Program and the European Commission (Horizon 2020, 7th Framework Programme); and an honorarium to participate in a symposium and contribute to the review of an article for the International Parkinson and Movement Disorder Society. Hubert Fernandez has acted as a consultant for Acorda Therapeutics, Amneal, Bial Neurology, CNS Ratings LLC, Denali Therapeutics, Kyowa Hakko Kirin, Pfizer, Partners Healthcare System/Parkinson Study Group, Revance Therapeutics, Sun Pharmaceutical Industries, Sunovion Research and Development Trust; as an independent contractor (including contracted research) for Acorda Therapeutics, Michael J Fox Foundation, Movement Disorders Society, National Institute of Health’s National Institute of Neurological Disorders and Stroke, Parkinson Study Group, Sunovion, Elsevier as the Editor in Chief of Parkinsonism & Related Disorders; and has been involved in teaching and speaking activities for the American Osteopathic Association, Bial, Cleveland Clinic, South Alabama Medical Science Foundation, Thoraxx Clinical Communications and Ultimate Medical Academy Education. Per Odin has received honoraria for consultancies, advisory boards and speaker activities from AbbVie, Britannia, Lundbeck, Nordic Infucare, Teva, UCB, Zambon and Bial; and has participated as an investigator in clinical studies performed by AbbVie and Britannia. Joaquim Ferreira has received payments for consultancy, advisory boards and grants from Abbott, AbbVie, Affiris, Allergan, Bial, Biogen, Fundação MSD (Portugal), GlaxoSmithKline, Grunenthal, Ipsen, Lundbeck, Medtronic, Merck Serono, Merz, MSD, Novartis, Solvay, Sunovion Pharmaceuticals, Teva and Zambon.

Compliance with Ethics

This article reports the proceedings of a sponsored satellite symposium and did not involve any studies with human or animal subjects performed by any of the authors.

Acknowledgements

Medical writing support was provided by Stuart Wakelin and Alex Lowe of Touch Medical Communications and funded by Bial


Click HERE to Register for the MS Beacon Newsletter


:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Please subscribe to the: 
   MS Learning Channel on @YouTube

Click Red Box on banner to opt-in
....................................................................................

This article is posted and shared by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
(Originally posted by Stuart)
  87 Hits

Copyright

© M.S. Views & News

87 Hits

NARCRMS ENROLLMENT MILESTONE: 700 MULTIPLE SCLEROSIS PARTICIPANTS ENROLLED

NARCRMS ENROLLMENT MILESTONE: 700 MULTIPLE SCLEROSIS PARTICIPANTS ENROLLED
**A press release shared with kind permission of our society partner, the Consortium of Multiple Sclerosis Centers (CMSC)**
Patient Registry is a Collaborative Public-Private Partnership Under the Auspices of the Consortium of Multiple Sclerosis Centers (CMSC)
(Hackensack, NJ, March 2020) — The North American Registry for Care and Research in MS (NARCRMS) is pleased to announce enrollment of its 700th patient on Wednesday, February 26, 2020. NARCRMS anticipates enrolling up to 1,250 patients across 30 sites in the US and Canada. The registry is committed to recruiting patients of diverse ethnic and racial backgrounds, with over 150 Hispanic patients and approximately 75 patients that self-identify as Black or African American enrolled to date.
The mission of NARCRMS is to provide clinicians and researchers with a greater, more integrated ability to track the incidence, prevalence and course of Multiple Sclerosis. Through information sharing, the registry seeks to improve the understanding of MS and facilitate care at every level. NARCRMS is unique as the first open source MS registry in the US and Canada that provides de-identified data to all stakeholders.
NARCRMS is a highly collaborative effort involving other MS registries, clinicians, researchers, and people living with MS and is endorsed by the National Multiple Sclerosis Society.
Read more


:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Please subscribe to the: 
   MS Learning Channel on @YouTube

Click Red Box on banner to opt-in
....................................................................................

This article is posted and shared by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
(Originally posted by Stuart)
  65 Hits

Copyright

© M.S. Views & News

65 Hits

First Coast Integrative Medicine listing of Resources for exercise, recipes and COVID items

First Coast Integrative Medicine listing of Resources for exercise, recipes and COVID items

First Coast Integrative Medicine Contact 
(sign up for email newsletters and helpful updates)



Resources for exercise and recipes

        www.yogamovesms.org
        https://www.msworkouts.com/


COVID-19 Wellness Resources

 

 
Resources for making and ordering masks

       https://www.thestytchbytch.com/collections/face-masks/Face-Masks


=============================================================


Click HERE to Register for the MS Beacon Newsletter


This information is posted and shared by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Original author: Stuart
  101 Hits

Copyright

© M.S. Views & News

101 Hits

MSChristian.org RSS Statement

Most of the information found on this website comes from RSS Feeds. It is an automated task that provides the information to you. We try to limit items that are duplicates, but with many feeds this can be difficult. Since the owner of this website also has MS and is legally blind this service was necessary to keep the website running with as much automation as possible. Volunteers help from time to time but many have disabilities themselves. We thank you for visiting us and hope that MSC can be of service to you and your loved ones.